...its rights to tislelizumab following the company’s acquisition by Bristol Myers Squibb Co. (NYSE:BMY). Virginia Li tislelizumab (BGB-A317) BeiGene...

...chromosome ten BioCentury Staff PCV-15 (V114) Contepo, fosfomycin (Zolyd, ZTI-01) Relumina (relugolix, TAK-385) ABI-M201 ABI-M301 ipatasertib (GDC-0068, RG7440) belantamab mafodotin, J6M0-mcMMAF (2857916, GSK2857916) tislelizumab (BGB-A317) Dupixent...

...tislelizumab plus chemotherapy met the primary endpoint of improving progression-free survival in the Phase III BGB-A317-304...

...reached a pre-specified threshold for improving progression-free survival, the primary endpoint in the Phase III BGB-A317-307...
...death 1; PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Sandi Wong, Assistant Editor tislelizumab (BGB-A317) BeiGene...

...for bladder cancer. Targets: PD-1 (PDCD1; CD279) - Programmed cell death 1 Hongjiang Li, Staff Writer tislelizumab (BGB-A317) BeiGene...

...cyd-tdv, ChimeriVax-Dengue) Recombinant Ebola virus vaccine (Ad5-EBOV) Rozlytrek, entrectinib (RG6268, rxdx-101) Vitrakvi, larotrectinib (LOXO-101) Zynteglo (LentiGlobin BB305 gene therapy) tislelizumab (BGB-A317) Zejula...

...upfront payment and is eligible for milestones; specific terms were not disclosed. BioCentury Staff Tuoyi, toripalimab (JS001) tislelizumab (BGB-A317) Solasia...

...Chemokine CC motif ligand 19; IL-7 - Interleukin-7; SGLT2 - Sodium-glucose cotransporter 2 BioCentury Staff tislelizumab (BGB-A317) Jardiance...

...rights to the cancer drugs from Celgene in return for licensing its PD-1 inhibitor tislelizumab (BGB-A317...

...27. BeiGene is also running both China and global trials for its PD-1 inhibitor tislelizumab (BGB-A317...
...Burton's tyrosine kinase; PD-1 (PDCD1; CD279) - Programmed cell death 1 Hongjiang Li, Staff Writer tislelizumab (BGB-A317) zanubrutinib...